Company news
Spruce Biosciences, Inc. news in 2026
Spruce Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.
Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
November 2, 2026
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
October 15, 2026
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
October 8, 2026
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Spruce Biosciences Announces Launch of MPS3BStudy.com
August 26, 2026
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
August 24, 2026
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
August 12, 2026
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
August 3, 2026
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
July 27, 2026
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
July 8, 2026
Spruce Biosciences Joins the Russell 3000® Index
June 29, 2026
Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
June 22, 2026
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
June 15, 2026
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
June 8, 2026
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
May 28, 2026
Spruce Biosciences to Participate in Upcoming Conferences in June
May 27, 2026
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 12, 2026
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
May 4, 2026
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
April 20, 2026
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
March 8, 2026
Spruce Biosciences to Present at Upcoming Investor Conferences in March
March 2, 2026
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
February 17, 2026
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
February 5, 2026
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
February 2, 2026
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
January 27, 2026
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
January 18, 2026
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
January 8, 2026
Decks in 2026
- Investor Presentation (August 2026)
Investor deck · 22 slides · Aug 12, 2026